Cargando…
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040877/ https://www.ncbi.nlm.nih.gov/pubmed/30018846 |